The latest news on cancer diagnostics, liquid biopsy, and cancer risk testing.
The Jerusalem-based drug developer is studying PLX8394 in patients with BRAF V600-mutated gliomas and solid tumors with non-V600 mutations.
A study presented at the NSGC annual meeting found that tumor analysis and germline testing yielded discordant results in almost a quarter of cases.
The study, presented at the NSGC annual conference last week, supports the broader use of panel testing for cancer patients suspected of hereditary disease.
The partnership goes hand-in-hand with Genentech's new precision basket trial, for which it will identify and enroll patients across OneOncology's network.
The regulatory submission triggers a milestone payment, and Invitae will issue 5 million shares of its common stock to former ArcherDx securityholders.
